1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Skin Infections - Pipeline Review, H1 2014

Skin Infections - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 183 pages

Skin Infections - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Skin Infections - Pipeline Review, H1 2014’, provides an overview of the Skin Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Skin Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Skin Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Skin Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Skin Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Skin Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Skin Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Skin Infections - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Skin Infections Overview 11
Therapeutics Development 12
Pipeline Products for Skin Infections - Overview 12
Pipeline Products for Skin Infections - Comparative Analysis 13
Skin Infections - Therapeutics under Development by Companies 14
Skin Infections - Therapeutics under Investigation by Universities/Institutes 17
Skin Infections - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Skin Infections - Products under Development by Companies 22
Skin Infections - Products under Investigation by Universities/Institutes 25
Skin Infections - Companies Involved in Therapeutics Development 26
GlaxoSmithKline plc 26
Takeda Pharmaceutical Company Limited 27
Melinta Therapeutics, Inc 28
The Medicines Company 29
Toyama Chemical Co., Ltd. 30
Wockhardt Limited 31
Paratek Pharmaceuticals, Inc. 32
CrystalGenomics, Inc. 33
Debiopharm International S.A. 34
Bharat Biotech International Limited 35
MerLion Pharmaceuticals Pte Ltd 36
Foamix Ltd. 37
Anacor Pharmaceuticals, Inc. 38
Destiny Pharma Ltd. 39
Nabriva Therapeutics AG 40
Atox Bio Inc. 41
Cempra, Inc. 42
Cellceutix Corporation 43
Tetraphase Pharmaceuticals Inc. 44
Lytix Biopharma AS 45
Durata Therapeutics, Inc. 46
MGB Biopharma Limited 47
Pergamum AB 48
Furiex Pharmaceuticals, Inc. 49
Microbion Corporation 50
Biota Pharmaceuticals, Inc. 51
Lipid Pharmaceuticals ehf. 52
Dong-A Socio Holdings Co Ltd 53
Skin Infections - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
dalbavancin - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
oritavancin disphosphate - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
ceftaroline fosamil - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
delafloxacin - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
tedizolid phosphate - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
ozenoxacin - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
GSK-1322322 - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
AFN-1252 - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
lysostaphin - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
omadacycline tosylate - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
brilacidin - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
radezolid - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
CG-400549 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
fusidic acid - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
LTX-109 - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
minocycline - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
AB-103 - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
avarofloxacin hydrochloride - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
WCK-2349 - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
GSK-2140944 - Drug Profile 103
Product Description 103
Mechanism of Action 103
RandD Progress 103
BC-7013 - Drug Profile 104
Product Description 104
Mechanism of Action 104
RandD Progress 104
AN-2718 - Drug Profile 105
Product Description 105
Mechanism of Action 105
RandD Progress 105
Bismuth ethanedithiol - Drug Profile 106
Product Description 106
Mechanism of Action 106
RandD Progress 106
Debio-1450 - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
Small Molecule for Skin Infections - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
DPD-207 - Drug Profile 109
Product Description 109
Mechanism of Action 109
RandD Progress 109
RX-04 - Drug Profile 110
Product Description 110
Mechanism of Action 110
RandD Progress 110
RX-02 - Drug Profile 111
Product Description 111
Mechanism of Action 111
RandD Progress 111
Gyrase Program - Drug Profile 112
Product Description 112
Mechanism of Action 112
RandD Progress 112
CaTx-II - Drug Profile 113
Product Description 113
Mechanism of Action 113
RandD Progress 113
MGB-BP-3 - Drug Profile 114
Product Description 114
Mechanism of Action 114
RandD Progress 114
acALY18 - Drug Profile 116
Product Description 116
Mechanism of Action 116
RandD Progress 116
Small Molecules for Skin and Soft Tissue and Community Acquired Pneumonia Infections - Drug Profile 117
Product Description 117
Mechanism of Action 117
RandD Progress 117
Monoclonal Antibodies Targeting ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile 118
Product Description 118
Mechanism of Action 118
RandD Progress 118
DBAF-101 - Drug Profile 119
Product Description 119
Mechanism of Action 119
RandD Progress 119
Small Molecules to Inhibit 50S RNA for Infections - Drug Profile 120
Product Description 120
Mechanism of Action 120
RandD Progress 120
KBP-7072 - Drug Profile 121
Product Description 121
Mechanism of Action 121
RandD Progress 121
siderocillin - Drug Profile 122
Product Description 122
Mechanism of Action 122
RandD Progress 122
finafloxacin - Drug Profile 123
Product Description 123
Mechanism of Action 123
RandD Progress 123
Peptides to Activate TLR-2 for Oncology and Dermatology - Drug Profile 125
Product Description 125
Mechanism of Action 125
RandD Progress 125
Small Molecule to Inhibit DHFR for cSSSI - Drug Profile 126
Product Description 126
Mechanism of Action 126
RandD Progress 126
DPK-060 - Drug Profile 127
Product Description 127
Mechanism of Action 127
RandD Progress 127
eravacycline - Drug Profile 128
Product Description 128
Mechanism of Action 128
RandD Progress 128
Skin Infections - Recent Pipeline Updates 130
Skin Infections - Dormant Projects 172
Skin Infections - Discontinued Products 173
Skin Infections - Product Development Milestones 174
Featured News and Press Releases 174
Apr 29, 2013: Durata Therapeutics Announces Presentation Of New Data Demonstrating In Vitro Potency Of Dalbavancin Against Bacterial Pathogens At 23rd Annual ECCMID Meeting 174
Dec 15, 2011: Rib-X Reports Positive Top-Line Data From Phase IIb Study Of Delafloxacin In Patients With Acute Bacterial Skin And Skin Structure Infections 174
Sep 15, 2011: Nabriva Therapeutics Presents Extended Phase II Results For Pleuromutilin Antibiotic BC-3781 176
Jun 06, 2011: Durata Therapeutics Announces Successful Production Of Clinical Supplies Of Dalbavancin 177
Apr 18, 2011: Nabriva Reports Positive Results from Phase II Trial Of Pleuromutilin Antibiotic BC-3781 In ABSSSI 177
Apr 18, 2011: Durata Therapeutics Initiates Phase III Study Of Dalbavancin For Treatment Of Acute Bacterial Skin And Skin Structure Infections 178
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva 179
Nov 29, 2010: The Medicines Company Reaches Agreement With FDA On SPA For Oritavancin Phase III Trials 180
Sep 07, 2010: Forest Receives FDA Advisory Committee Approval For Ceftaroline Fosamil For Treatment Of CABP And cSSSI 180
Sep 01, 2010: Lytix Biopharma Receives Hungarian Approval To Start Phase IIa Clinical Trial With Lytixar In Gram Positive Skin Infections 181
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 183
Disclaimer 183

List of Tables

Number of Products under Development for Skin Infections, H1 2014 12
Number of Products under Development for Skin Infections - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Comparative Analysis by Unknown Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Development by Companies, H1 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2014 25
Skin Infections - Pipeline by GlaxoSmithKline plc, H1 2014 26
Skin Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 27
Skin Infections - Pipeline by Melinta Therapeutics, Inc, H1 2014 28
Skin Infections - Pipeline by The Medicines Company, H1 2014 29
Skin Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2014 30
Skin Infections - Pipeline by Wockhardt Limited, H1 2014 31
Skin Infections - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 32
Skin Infections - Pipeline by CrystalGenomics, Inc., H1 2014 33
Skin Infections - Pipeline by Debiopharm International S.A., H1 2014 34
Skin Infections - Pipeline by Bharat Biotech International Limited, H1 2014 35
Skin Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2014 36
Skin Infections - Pipeline by Foamix Ltd., H1 2014 37
Skin Infections - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 38
Skin Infections - Pipeline by Destiny Pharma Ltd., H1 2014 39
Skin Infections - Pipeline by Nabriva Therapeutics AG, H1 2014 40
Skin Infections - Pipeline by Atox Bio Inc., H1 2014 41
Skin Infections - Pipeline by Cempra, Inc., H1 2014 42
Skin Infections - Pipeline by Cellceutix Corporation, H1 2014 43
Skin Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2014 44
Skin Infections - Pipeline by Lytix Biopharma AS, H1 2014 45
Skin Infections - Pipeline by Durata Therapeutics, Inc., H1 2014 46
Skin Infections - Pipeline by MGB Biopharma Limited, H1 2014 47
Skin Infections - Pipeline by Pergamum AB, H1 2014 48
Skin Infections - Pipeline by Furiex Pharmaceuticals, Inc., H1 2014 49
Skin Infections - Pipeline by Microbion Corporation, H1 2014 50
Skin Infections - Pipeline by Biota Pharmaceuticals, Inc., H1 2014 51
Skin Infections - Pipeline by Lipid Pharmaceuticals ehf., H1 2014 52
Skin Infections - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 53
Assessment by Monotherapy Products, H1 2014 54
Number of Products by Stage and Target, H1 2014 57
Number of Products by Stage and Mechanism of Action, H1 2014 60
Number of Products by Stage and Route of Administration, H1 2014 62
Number of Products by Stage and Molecule Type, H1 2014 64
Skin Infections Therapeutics - Recent Pipeline Updates, H1 2014 130
Skin Infections - Dormant Projects, H1 2014 172
Skin Infections - Discontinued Products, H1 2014 173

List of Figures
Number of Products under Development for Skin Infections, H1 2014 12
Number of Products under Development for Skin Infections - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 54
Number of Products by Top 10 Target, H1 2014 55
Number of Products by Stage and Top 10 Target, H1 2014 56
Number of Products by Top 10 Mechanism of Action, H1 2014 58
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 59
Number of Products by Top 10 Route of Administration, H1 2014 61
Number of Products by Stage and Top 10 Route of Administration, H1 2014 62
Number of Products by Top 10 Molecule Type, H1 2014 63
Number of Products by Stage and Top 10 Molecule Type, H1 2014 64

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Benzyl alcohol is an aromatic alcohol, which is metabolized into benzoic acid inthe human body. Benzyl alcohol is manufactured by hydrolysis of benzyl chloride in the presence of soda ash through the toluene ...

Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Global Feed Antibiotics Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Ghana

  • December 2016
    10 pages
  • Anti-Infective  

  • Ghana  

View report >

Anti-Infective Market in Canada

  • November 2016
    215 pages
  • Anti-Infective  

    Civil Protectio...  

    Environment  

  • Canada  

    North America  

View report >

Therapy Market in India, Monthly Update

  • November 2016
    37 pages
  • Therapy  

View report >

Anti-infective Market

18 days ago

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.